<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391817</url>
  </required_header>
  <id_info>
    <org_study_id>FMTOBE</org_study_id>
    <nct_id>NCT03391817</nct_id>
  </id_info>
  <brief_title>FAECAL MICROBIOTA TRANSPLANTATION IN OBESITY</brief_title>
  <official_title>FAECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF MORBID OBESITY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Authority for Päijät-Häme Social and Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joint Authority for Päijät-Häme Social and Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      40 patients meeting the criteria for obesity surgery are enrolled. Fecal microbiota
      transplantation (FMT) will be administered in gastroscopy 6 months before obesity surgery. 20
      of the patients will receive a fecal transplant of a thin donor and 20 will receive placebo -
      a transplant made of their on feces. Changes in weight, laboratory values, general well being
      and stool microbiota will be measured up to one year after the surgery; one and a half years
      after FMT. The hypothesis is that FMT and the change in gut microbiota will help to reduce
      and maintain lower weight.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of weight</measure>
    <time_frame>1,5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fecal transplant from a thin donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fecal transplant made from patients own feces</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbiota transplantation</intervention_name>
    <description>Fecal microbiota transplantation administered in gastroscopy</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Candidates for the bariatric surgery

        BMI ≥ 40 or BMI ≥35 and at least two obesity-related co-morbidities such as type II
        diabetes (T2DM), hypertension, sleep apnea and other respiratory disorders, non-alcoholic
        fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or
        heart disease.

          -  Availability of consecutive fecal samples during one year

          -  Compliance to attend gastroscopy and FMT

          -  18-65 years

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Pregnancy

          -  Type I Diabetes Mellitus

          -  Severe renal insufficiency, GFR&lt;30%

          -  Chronic or recurrent bacterial infection needing antimicrobial treatment

          -  Large hiatal hernia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perttu Arkkila, PhD MD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perttu Lahtinen, MD</last_name>
    <phone>+358447195256</phone>
    <email>perttu.lahtinen@phhyky.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perttu Lahtinen, MD</last_name>
      <phone>+358447195256</phone>
      <email>perttu.lahtinen@phhyky.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perttu Lahtinen, MD</last_name>
      <phone>+358447195256</phone>
      <email>perttu.lahtinen@phhyky.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

